The role of neuroimaging and electrophysiology (EEG) as predictors of treatment response in major depressive disorder

Clinical Neuropsychiatry

Volumn 8, Issue 1, 2011, Pages 47-60

  Iosifescu, Dan V ^a   Lapidus, Kyle ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Major depressive disorder; Neuroimaging; Quantitative EEG; Treatment selection

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

BRAIN BLOOD FLOW; BRAIN REGION; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DRUG BRAIN LEVEL; ELECTROENCEPHALOGRAPHY; EVENT RELATED POTENTIAL; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; LOW RESOLUTION BRAIN ELECTROMAGNETIC TOMOGRAPHY; MAJOR DEPRESSION; MEDICAL LITERATURE; MENTAL HEALTH CARE; MOOD; MORPHOMETRICS; NERVE CELL NETWORK; NEUROCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSESSIVE COMPULSIVE DISORDER; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOPHARMACOLOGY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THETA RHYTHM; TREATMENT RESPONSE; WHITE MATTER;

EID: 79955686245     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Aftanas LI, Golocheikine SA (2001). Human anterior and frontal midline theta and lower alpha reflect emotionally positive state and internalized attention: high-resolution EEG investigation of meditation. Neurosci Lett 310, 1, 57-60.
2. Aftanas LI, Varlamov AA, Reva NV, Pavlov SV (2003). Disruption of early event-related theta synchronization of human EEG in alexithymics viewing affective pictures. Neurosci Lett 340, 1, 57-60.
3. Adinoff B, Devous MD (2010). Scientifically unfounded claims in diagnosing and treating patients. J Psychiatry 167, 598-598.
4. Alexopoulos GS, Meyers BS, Young RC, Kakuma T, Silbersweig D, Charlson M (1997). Clinically defined vascular depression. Am J Psychiatry 154, 4, 562-5.
5. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. (1997). Vascular depression' hypothesis. Arch Gen Psychiatry 54, 10, 915-22.
6. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, Latoussakis V, Kanellopoulos D, Klimstra S, Lim Ko,Hoptman MJ (2009). Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry 165, 2, 238-44.
7. Alexopoulos GS, Kiosses DN, Choi SJ, Murphy CF, Lim KO (2002). Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry 159, 11,1929-32.
8. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, Mathews VP, Kalnin A, Lowe MJ (2005). Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry 57,10, 1079-88.
9. Anand A, Li Y, Wang Y, Gardner K, Lowe MJ (2007). Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci 19, 3, 274-82.
10. Asada H, Fukuda Y, Tsunoda S, Yamaguchi M, Tonoike M (1999). Frontal midline theta rhythms reflect alternative activation of prefrontal cortex and anterior cingulate cortex in humans. Neurosci Lett 274, 1, 29-32.
11. Auer DP, Piitz B, Kraft E, Lipinski B, Schill J, Holsboer F (2000). Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 47, 4, 305-13.
12. Bares M, Brunovsky M, Kopecek M, Stopkova P, Novak T, Kozeny J, Hoschl C (2007). Changes in QEEG prefrontal cordance as a predictor of response to antidepressants in patients with treatment resistant depressive disorder: a pilot study. J Psychiatr Res 41, 3-4, 319-25.
13. Bares M, Brunovsky M, Kopecek M, Novak T, Stopkova P, Kozeny J, Sos P, Krajca V, Hoschl C (2008). Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder. Eur Psychiatry 23, 5, 350-5.
14. Basjar E, Schiirmann M, Sakowitz O (2001). The selectively distributed theta system: functions. Int J Psychophysiol 39, 2-3, 197-212.
15. Baxter LR Jr, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE, Gerner RH, Sumida RM (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46, 3, 243-50.
16. Bernier D, Bartha R, Devarajan S, Macmaster FP, Schmidt MH, Rusak B (2009).Effects of overnight sleep restriction on brain chemistry and mood in women with unipolar depression and healthy controls. J Psychiatry Neurosci 34, 5, 352-60.
17. Bots ML, van Swieten JC, Breteler MM, de Jong PT, van Gijn J, Hofman A, Grobbee DE (1993). Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 341, 885, 1232-7.
18. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS (2002). Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51, 4, 273-9.
19. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, Phelps ME, Huang SC, Wu HM, Ho ML, Ho MK, Au SC, Maidment K, Baxter LR Jr (2001). Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry 58, 7, 631-40.
20. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, Huang SC, Wu HM, Maidment K, Baxter LR Jr (1999). Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res 91, 3, 127-39.
21. Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM (2001). Electroence-phalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry 49, 5, 416-25.
22. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, Reynolds C (1997). Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 41, 1, 15-22.
23. Chen CH, Ridler K, Suckling J, Williams S, Fu CH, Merlo-Pich E, Bullmore E (2007). Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry 62, 5, 407-14.
24. Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, Heuser I (2007). Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res 41, 7, 553-60.
25. Cook IA, Leuchter AF (2001). Prefrontal changes and treatment response prediction in depression. SeminClin Neuropsychiatry 6, 2, 113-20.
26. Cook IA, Leuchter AF, Morgan ML, Stubbeman W, Siegman B, Abrams M (2005). Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res 39, 5, 461-6.
27. Cotter D, Mackay D, Landau S, Kerwin R, Everall I (2001). Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 58, 6, 545-53.
28. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS (2005) Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry 57, 12, 1526-34.
29. Dager SR, Corrigan NM, Richards TL, Posse S (2008). Research applications of magnetic resonance spectroscopy to investigate psychiatric disorders. Top Magn Reson Imaging 19, 2, 81-96.
30. de Groot JC, de Leeuw FE, Oudkerk M, Hofman A, Jolles J, Breteler MM (2000). Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry 57, 11, 1071-6.
31. Drevets WC (2000). Neuroimaging studies of mood disorders. Biol Psychiatry 48, 8, 813-29.
32. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME (1997). Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 6627, 824-7.
33. Drevets WC, Price JL, Bardgett ME, Reich T, Todd RD, Raichle ME (2001). Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels. Pharmacol Biochem Behav 71, 3, 431-47.
34. Drevets WC, Price JL, Furey ML (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct 213, 1-2, 93-118.
35. Drugan RC, Morrow AL, Weizman R, Weizman A, Deutsch SI, Crawley JN, Paul SM (1989). Stress-induced behavioral depression in the rat is associated with a decrease in GABA receptor-mediated chloride ion flux and brain benzodiazepine receptor occupancy. Brain Res 487, 1, 45-51.
36. Ehrlich S, Breeze JL, Hesdorffer DC, Noam GG, Hong X, Alban RL, Davis SE, Renshaw PF (2005). White matter hyperintensities and their association with suicidality in depressed young adults. J Affect Disord 86, 2-3, 281-7.
37. Ende G, Braus DF, Walter S, Weber-Fahr W, Henn FA (2000). The hippocampus in patients treated with electroconvulsive therapy: a proton magnetic resonance spectroscopic imaging study. Arch Gen Psychiatry 57, 10, 937-43.
38. Fava, M, Davidson KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19, 2, 179-200.
39. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. (2008). A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 29, 6, 683-95.
40. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Jager M, Groll C, Bottlender R, Leinsinger G, Moller HJ 2003). Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry 53, 4, 338-44.
41. Gabbay V, Hess DA, Liu S, Babb JS, Klein RG, Gonen O (2007). Lateralized caudate metabolic abnormalities in adolescent major depressive disorder: a proton MR spectroscopy study. Am J Psychiatry 164, 12, 1881-9.
42. Gallinat J, Bottlender R, Juckel G, Munke-Puchner A, Stotz G, Kuss HJ, Mavrogiorgou P, Hegerl U (2000). The loudness dependency of the auditory evoked N1/P2-component as a predictor of the acute SSRI response in depression. Psychopharmacology (Berl). 148, 4, 404-11.
43. Gerner RH, Fairbanks L, Anderson GM, Young JG, Scheinin M, Linnoila M, Hare TA, Shaywitz BA, Cohen DJ (1984). CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry 141,12, 1533-40.
44. Godin O, Dufouil C, Maillard P, Delcroix N, Mazoyer B, Cri-vello F, Alperovitch A, Tzourio C (2008). White matter lesions as a predictor of depression in the elderly: the 3C-Dijon study. Biol Psychiatry 63, 7, 6639.
45. Grimm S, Beck J, Schuepbach D, Hell D, Boesiger P, Bermpohl F, Niehaus L, Boeker H, Northoff G (2008). Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biol Psychiatry 63, 4, 369-76.
46. Grimm S, Boesiger P, Beck J, Schuepbach D, Bermpohl F, Walter M, Ernst J, Hell D, Boeker H, Northoff G (2009). Altered negative BOLD responses in the default-mode network during emotion processing in depressed subjects. Neuropsychopharmacology 34, 4, 932-843.
47. Guidotti A, Costa E (1998). Can the antidysphoric and anxiolytic profiles of selective serotonin reuptake inhibitors be related to their ability to increase brain 3 alpha, 5 alpha-tetrahydroprogesterone (allopregnanolone) availability? Biol Psychiatry 44, 9, 865-73.
48. Hajek T, Kozeny J, Kopecek M, Alda M, Hoschl C (2008). Reduced subgenual cingulate volumes in mood disorders: a meta-analysis. J Psychiatry Neurosci 33, 2, 91-9.
49. Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61, 2, 105-23.
50. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007). Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64, 2, 193-200.
51. Hasler G, Neumeister A, van der Veen JW, Tumonis T, Bain EE, Shen J, Drevets WC, Charney DS (2005). Normal prefrontal gamma-aminobutyric acid levels in remitted depressed subjects determined by proton magnetic resonance spectroscopy. Biol Psychiatry 58,12, 969-73.
52. Hegerl U, Gallinat J, Juckel G (2001). Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62,1-2, 93-100.
53. Heikman P, Salmelin R, Makela JP, Hari R, Katila H, Kuoppasalmi K (2001). Relation between frontal 3-7 Hz MEG activity and the efficacy of ECT in major depression. J ECT 17, 2, 136-40.
54. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF (2000). Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 157, 9, 1506-8.
55. Hoptman MJ, Gunning-Dixon FM, Murphy CF, Ardekani BA, Hrabe J, Lim KO, Etwaroo GR, Kanellopoulos D, Alexopoulos GS (2009). Blood pressure and white matter integrity in geriatric depression. J Affect Disord 115, 1-2, 171-6.
56. Huang Y, Chen W, Li Y, Wu X, Shi X, Geng D (2010). Effects of antidepressant treatment on N-acetyl aspartate and choline levels in the hippocampus and thalami of post-stroke depression patients: a study using (1).H magnetic resonance spectroscopy. Psychiatry Res 182, 1, 48-52.
57. Hunter AM, Leuchter AF, Morgan ML, Cook IA, Abrams M, Siegman B, DeBrota DJ, Potter WZ (2005). Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology 30, 4, 792-9.
58. Hunter AM, Leuchter AF, Cook IA, Abrams M (2010). Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. Acta Psychiatr Scand 122, 6, 461-9.
59. Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Perlis RH, Papakostas GI, Nierenberg AA, Fava M (2006). Brain white-matter hyperintensities and treatment outcome in major depressive disorder. Br J Psychiatry 188, 180-5.
60. Iosifescu DV, Papakostas GI, Lyoo IK, Lee HK, Renshaw PF, Alpert JE, Nierenberg A, Fava M (2005). Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part I). Psychiatry Res 140, 3, 291-9.
61. Iosifescu DV, Renshaw PF, Dougherty DD, Lyoo IK, Lee HK, Fraguas R, Cassano P, Nierenberg AA, Fava M (2007). Major depressive disorder with anger attacks and subcortical MRI white matter hyperintensities. J Nerv Ment Dis 195, 2, 175-8.
62. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, Nierenberg AA, Fava M (2005). Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 67, 5, 703-6.
63. Iosifescu DV, Bolo NR, Nierenberg AA, Jensen JE, Fava M, Renshaw PF (2008). Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder. Biol Psychiatry 63, 12, 1127-34.
64. Iosifescu DV, Renshaw PE (2003). 31P-magnetic resonance spectroscopy and thyroid hormones in major depressive disorder: toward a bioenergetic mechanism in depression? Harv Rev Psychiatry 11, 2, 51-63.
65. Iosifescu DV, Greenwald S, Devlin P, Mischoulon D, Denninger JW, Alpert JE, Fava M (2009). Frontal EEG predictors of treatment outcome in major depressive disorder. Eur Neuropsychopharmacol 19, 11, 7727.
66. Iosifescu DV, Greenwald S, Devlin P, Perlis RH, Denninger JW, Alpert JE, Fava M (2008). Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand 117, 4, 271-6
67. Ishii R, Shinosaki K, Ukai S, Inouye T, Ishihara T, Yoshimine T, Hirabuki N, Asada H, Kihara T, Robinson SE, Takeda M (1999). Medial prefrontal cortex generates frontal midline theta rhythm. Neuroreport 10, 4, 675-9.
68. Ito H, Kawashima R, Awata S, Ono S, Sato K, Goto R, Koyama M, Sato M, Fukuda H (1996). Hypoperfusion in the limbic system and prefrontal cortex in depression: SPECT with anatomic standardization technique. J Nucl Med 37, 3, 410-4.
69. Kato T,Inubushi T,Kato N (1998). Magnetic resonance spectroscopy in affective disorders. J Neuropsychiatry Clin Neurosci 10, 2, 133-47.
70. Kaymak SU, Demir B, Sentürk S, Tatar I, Aldur MM, Ulud B (2010). Hippocampus, glucocorticoids and neurocognitive functions in patients with first-episode major depressive disorders. Eur Arch Psychiatry Clin Neurosci 260, 3, 217-23.
71. Keedwell PA, Drapier D, Surguladze S, Giampietro V, Brammer M, Phillips M (2010). Subgenual cingulate and visual cortex responses to sad faces predict clinical outcome during antidepressant treatment for depression. J Affect Disord 120, 1-3, 120-5.
72. Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, Campbell C, Oquendo M, Van Heertum RL, Mann JJ (2003). Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. Am J Psychiatry 160, 1, 76-82.
73. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ (2001). Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 158, 6, 899-905
74. Knott VJ, Telner JI, Lapierre YD, Browne M, Horn ER (1996). Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord 39, 3, 175-84.
75. Knott V, Mahoney C, Kennedy S, Evans K (2002). EEG correlates of acute and chronic paroxetine treatment in depression. J Affect Disord 69, 1-3, 241-9.
76. Kram ML, Kramer GL, Steciuk M, Ronan PJ, Petty F (????). Effects of learned helplessness on brain GABA receptors. Neurosci Res 38, 2, 193-8.
77. Krishnan KR, Hays JC, Blazer DG (1997). MRI-defined vascular depression. Am J Psychiatry 154, 4, 497-501.
78. Lacerda AL, Nicoletti MA, Brambilla P, Sassi RB, Mallinger AG, Frank E, Kupfer DJ, Keshavan MS, Soares JC (2003). Anatomical MRI study of basal ganglia in major depressive disorder. Psychiatry Res 124, 3, 129-40.
79. Langenecker SA, Kennedy SE, Guidotti LM, Briceno EM, Own LS, Hooven T, Young EA, Akil H, Noll DC, Zubieta JK (2007). Frontal and limbic activation during inhibitory control predicts treatment response in major depressive disorder. Biol Psychiatry 62, 11, 1272-80.
80. Larisch R, Klimke A, Vosberg H, Loffler S, Gaebel W, Muller-Gartner HW (1997). In vivo evidence for the involvement of dopamine-D2 receptors in striatum and anterior cingulate gyrus in major depression. Neuroimage 5, 4 Pt 1, 251-60.
81. Lee BT, Seok JH, Lee BC, Cho SW, Yoon BJ, Lee KU, Chae JH, Choi IG, Ham BJ (2008). Neural correlates of affective processing in response to sad and angry facial stimuli in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 32, 3, 778-85.
82. Lemonde S, Turecki G, Bakish D, Du L, Hrdina PD, Bown CD, Sequeira A, Kushwaha N, Morris SJ, Basak A, Ou XM, Albert PR (2003). Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J Neurosci 23, 25, 8788-99.
83. Lenze E, Cross D, McKeel D, Neuman RJ, Sheline YI (1999). White matter hyperintensities and gray matter lesions in physically healthy depressed subjects. Am J Psychiatry 156, 10, 1602-7.
84. Leuchter AF, Cook IA, Marangell LB, Gilmer WS, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, McCracken JT, Fava M, Iosifescu D, Greenwald S (2009). Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. Psychiatry Res 169, 2, 124-31.
85. Leuchter AF, Cook IA, Gilmer WS, Marangell LB, Burgoyne KS, Howland RH, Trivedi MH, Zisook S, Jain R, Fava M, Iosifescu D, Greenwald S (2009). Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res 169, 2, 132-8.
86. Leuchter AF, Uijtdehaage SH, Cook IA, O'Hara R, Mandelkern M (1999). Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res 90, 2, 125-40.
87. Leuchter AF, Cook IA, Uijtdehaage SH, Dunkin J, Lufkin RB, Anderson-Hanley C, Abrams M, Rosenberg Thompson S, O'Hara R, Simon SL, Osato S, Babaie A (1997). Brain structure and function and the outcomes of treatment for depression. J Clin Psychiatry 58, 16, 22-31.
88. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M (2002). Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry 159, 1, 122-9.
89. Leuchter AF (2009). Healing the hardware of the soul: enhance your brain to improve your work, love, and spiritual life, by Daniel Amen (book review). Am J Psychiatry 166, 625.
90. Lorenzetti V, Allen NB, Fornito A, Yucel M (2009). Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies. J Affect Disord 117, 1-2, 1-17.
91. Li L, Ma N, Li Z, Tan L, Liu J, Gong G, Shu N, He Z, Jiang T, Xu L (2007). Prefrontal white matter abnormalities in young adult with major depressive disorder: a diffusion tensor imaging study. Brain Res 1168, 124-8.
92. Linka T, Muller BW, Bender S, Sartory G (2004). The intensity dependence of the auditory evoked N1 component as a predictor of response to Citalopram treatment in patients with major depression. Neurosci Lett 367, 3, 375-8.
93. Little JT, Ketter TA, Kimbrell TA, Danielson A, Benson B, Willis MW, Post RM (1996). Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacol Bul. 32, 4, 629-35.
94. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, Luckenbaugh DA, Post RM (2005). Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biol Psychiatr 57, 3, 220-8.
95. Lyoo IK, Lee HK, Jung JH, Noam GG, Renshaw PF (2002). White matter hyperintensities on magnetic resonance imaging of the brain in children with psychiatric disorders. Compr Psychiatry 43, 5, 361-8.
96. Lyoo IK, Renshaw PF (2002). Magnetic resonance spectroscopy: current and future applications in psychiatric research. Biol Psychiatry 51, 3, 195-207.
97. Ma N, Li L, Shu N, Liu J, Gong G, He Z, Li Z, Tan L, Stone WS, Zhang Z, Xu L, Jiang T (2007). White matter abnormalities in first-episode, treatment-naive young adults with major depressive disorder. Am J Psychiatry 164, 5, 823-6.
98. MacMaster FP, Mirza Y, Szeszko PR, Kmiecik LE, Easter PC, Taormina SP, Lynch M, Rose M, Moore GJ, Rosenberg DR (2008). Amygdala and hippocampal volumes in familial early onset major depressive disorder. Biol Psychiatry 63, 4, 385-90.
99. MacMaster FP, Kusumakar V (2004). Hippocampal volume in early onset depression. BMC Med 29, 2, 2.
100. Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nat Med 7, 5, 541-7.
101. Martinot JL, Hardy P, Feline A, Huret JD, Mazoyer B, Attar-Levy D, Pappata S, Syrota A (1990). Left prefrontal glucose hypometabolism in the depressed state: a confirmation. Am J Psychiatry 147,10, 1313-7.
102. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT (1997). Cingulate function in depression: a potential predictor of treatment response. Neuroreport 8, 4,1057-61.
103. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, Silva JA, Tekell JL, Martin CC, Lancaster JL, Fox PT (1999). Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 156, 5, 675-82.
104. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA (2002). The functional neuro-anatomy of the placebo effect. Am J Psychiatry 159, 5, 728-37.
105. McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009). A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 34, 1, 41-54.
106. Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV (2008). Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. J Psychiatr Res 42, 14, 1137-44.
107. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF (1997). Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry 154, 1, 1168.
108. Murck H, Schubert MI, Schmid D, Schissler P, Steiger A, Auer DP (2009). The glutamatergic system and its relation to the clinical effect of therapeutic-sleep deprivation in depression-an MR spectroscopy study. J Psychiatr Res 43, 3, 175-80.
109. Neumeister A, Drevets WC, Belfer I, Luckenbaugh DA, Henry S, Bonne O, Herscovitch P, Goldman D, Charney DS (2006). Effects of a alpha 2C-adrenoreceptor gene polymorphism on neural responses to facial expressions in depression. Neuropsychopharmacology 31, 8, 1750-6.
110. Nordanskog P, Dahlstrand U, Larsson MR, Larsson EM, Knutsson L, Johanson A (2010). Increase in hippocampal volume after electroconvulsive therapy in patients with depression: a volumetric magnetic resonance imaging study. J ECT 26,1,62-7.
111. O'Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N (2004). A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. Am J Psychiatry 161,11, 2081-90.
112. Ongur D, Drevets WC, Price JL (1998). Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95, 22, 13290-5.
113. Paige SR, Fitzpatrick DF, Kline JP, Balogh SE, Hendricks SE. (1994). Event-related potential amplitude/intensity slopes predict response to antidepressants. Neuropsychobiology 30, 4, 197-201.
114. Paige SR, Hendricks SE, Fitzpatrick DF, Balogh S, Burke WJ (1995). Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. Psychopharmacol Bull 31, 2, 243-8.
115. Papakostas GI, Iosifescu DV, Renshaw PF, Lyoo IK, Lee HK, Alpert JE, Nierenberg AA, Fava M (2005). Brain MRI white matter hyperintensities and one-carbon cycle metabolism in non-geriatric outpatients with major depressive disorder (Part II). Psychiatry Res 140, 3, 3017.
116. Paranthaman R, Greenstein AS, Burns AS, Cruickshank JK, Heagerty AM, Jackson A, Malik RA, Scott ML, Baldwin RC (2010). Vascular Function in Older Adults with Depressive Disorder. Biol Psychiatry 68, 2, 133-139.
117. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, Van Heertum RL, Arango V, Mann JJ (2006). Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 59, 2, 106-13.
118. Pezawas L, Meyer-Lindenberg A, Goldman AL, Verchinski BA, Chen G, Kolachana BS, Egan MF, Mattay VS, Hariri AR, Weinberger DR (2008). Evidence of biologic epistasis between BDNF and SLC6A4 and implications for depression. Mol Psychiatry 13, 7, 709-16.
119. Phelps ME, Mazziotta JC, Baxter L, Gerner R (1984). Positron emission tomographic study of affective disorders: problems and strategies. Ann Neurol 15 Suppl, S149-56.
120. Pizzagalli DA, Oakes TR, Fox AS, Chung MK, Larson CL, Abercrombie HC, Schaefer SM, Benca RM, Davidson RJ. (2004). Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry 9, 4, 325, 393-405
121. Pizzagalli D, Pascual-Marqui RD, Nitschke JB, Oakes TR, Larson CL, Abercrombie HC, Schaefer SM, Koger JV, Benca RM, Davidson RJ (2001). Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry 158, 3, 405-15
122. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA (1999). Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45, 9, 1085-98.
123. Renshaw PF, Lafer B, Babb SM, Fava M, Stoll AL, Christensen JD, Moore CM, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothschild AJ, Nierenberg AA, Rosenbaum JF, Cohen BM (1997). Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry 41, 8, 837-43.
124. Renshaw PF, Parow AM, Hirashima F, Ke Y, Moore CM, Frederick Bde B, Fava M, Hennen J, Cohen BM (2001). Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression. Am tPsychiatry 158, 12, 2048-55.
125. Rosenberg DR, Macmaster FP, Mirza Y, Smith JM, Easter PC, Banerjee SP, Bhandari R, Boyd C, Lynch M, Rose M, Ivey J, Villafuerte RA, Moore GJ, Renshaw P (2005). Reduced anterior cingulate glutamate in pediatric major depression: a magnetic resonance spectroscopy study. Biol Psychiatry 58, 9, 700-4.
126. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks WM, (2005). Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry 162, 2, 394-6.
127. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry 163, 11, 1905-17.
128. Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, Nierenberg AA (2009). STARD: revising conventional wisdom. CNS Drugs 23, 8, 627-47.
129. Savitz, JB, Drevets WC (2009). Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience 164, 1, 300-30.
130. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH (1999). Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy. Arch Gen Psychiatry 56, 11, 1043-7.
131. Sanacora G, Mason GF, Rothman DL, Krystal JH (2002). Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159, 4, 663-5.
132. Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, Berman RM, Krystal JH (2003). Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 160, 3, 577-9.
133. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF (2004). Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61, 7, 705-13.
134. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR Jr (2003). Differential brain metabolic predictors of response to paroxetine in obsessive-compulsive disorder versus major depression. Am J Psychiatry 160, 3, 522-32.
135. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho MK, Huang SC, Wu HM, Baxter LR Jr (2002). Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Arch Gen Psychiatry 59, 3, 250-61.
136. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW. (1996). Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 93, 9, 3908-13.
137. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999). Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19, 12, 5034-43.
138. Sheline YI, Pieper CF, Barch DM, Welsh-Boehmer K, McKinstry RC, MacFall JR, D'Angelo G, Garcia KS, Gersing K, Wilkins C, Taylor W, Steffens DC, Krishnan RR, Doraiswamy PM (2010). Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry 67, 3, 277-85.
139. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, Mintun MA (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry 50, 9, 651-8.
140. Siegle GJ, Steinhauer SR, Thase ME, Stenger VA, Carter CS (2002). Can't shake that feeling: event-related fMRI assessment of sustained amygdala activity in response to emotional information in depressed individuals. Biol Psychiatry 51, 9, 693-707.
141. Simpson S, Baldwin RC, Jackson A, Burns AS (1998). Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med 28, 5, 1015-26.
142. Sonawalla SB, Renshaw PF, Moore CM, Alpert JE, Nierenberg AA, Rosenbaum JF, Fava M (1999). Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry 156, 10, 1638-40.
143. Steingard RJ, Yurgelun-Todd DA, Hennen J, Moore JC, Moore CM, Vakili K, Young AD, Katic A, Beardslee WR, Renshaw PF (2000). Increased orbitofrontal cortex levels of choline in depressed adolescents as detected by in vivo proton magnetic resonance spectroscopy. Biol Psychiatry 48, 11, 1053-61.
144. Strauss WL, Layton ME, Hayes CE, Dager SR (1997). 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 154, 4, 516-22.
145. Taylor WD, Zuchner S, McQuoid DR, Payne ME, MacFall JR, Steffens DC, Speer MC, Krishnan KR (2008). The brain-derived neurotrophic factor VAL66MET polymorphism and cerebral white matter hyperintensities in late-life depression. Am J Geriatr Psychiatry 16, 4, 263-71.
146. Thomas AJ, O'Brien JT, Davis S, Ballard C, Barber R, Kalaria RN, Perry RH (2002). Ischemic basis for deep white matter hyperintensities in major depression: a neuropathological study. Arch Gen Psychiatry 59, 9, 785-92.
147. Ulrich G, Renfordt E, Zeller G, Frick K (1984). Interrelation between changes in the EEG and psychopathology under pharmacotherapy for endogenous depression. A contribution to the predictor question. Pharmacopsychiatry 17, 6, 178-83.
148. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998). Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95, 6, 3239-44.
149. Vasic N, Walter H, Hose A, Wolf RC (2008). Gray matter reduction associated with psychopathology and cognitive dysfunction in unipolar depression: a voxel-based morphometry study. J Affect Disord 109, 12, 107-16.
150. Vinogradova OS (1995). Expression, control, and probable functional significance of the neuronal theta rhythm. Prog Neurobiol 45, 6, 523-83.
151. Volz HP, Rzanny R, Riehemann S, May S, Hegewald H, Preussler B, Hiibner G, Kaiser WA, Sauer H (1998). 51P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci 248, 6, 289-95.
152. Yildiz-Yesiloglu A, Ankerst DP (2006). Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 147, 1, 1-25.
153. Zobel A, Jessen F, von Widdern O, Schuhmacher A, Hofels S, Metten M, Rietschel M, Scheef L, Block W, Becker T, Schild HH, Maier W, Schwab SG (2008). Unipolar depression and hippocampal volume: impact of DNA sequence variants of the glucocorticoid receptor gene. Am J Med Genet B Neuropsychiatr Genet 147B, 6, 836-43.